TY - JOUR
T1 - Polymer-Functionalized Mitochondrial Transplantation to Fibroblasts Counteracts a Pro-Fibrotic Phenotype
AU - Baudo, Gherardo
AU - Wu, Suhong
AU - Massaro, Matteo
AU - Liu, Haoran
AU - Lee, Hyunho
AU - Zhang, Aijun
AU - Hamilton, Dale J
AU - Blanco, Elvin
N1 - Funding Information:
This work was supported by a Department of Defense (DOD) grant (W81XWH-19-1-0129) to E.B.
Funding Information:
All schematics were created with BioRender.com . The authors acknowledge the Mouse Metabolism and Phenotyping Core (MMPC) at the Baylor College of Medicine (BCM, funded by NIH grants RO1DK114356 and UM1HG006348). G.B. and M.M. are grateful for the support from the ANSO Scholarship for Young Talents, the University of the Chinese Academy of Sciences, and the College of Material Science and Opto-electronic Technology.
Publisher Copyright:
© 2023 by the authors.
PY - 2023/6/30
Y1 - 2023/6/30
N2 - Fibroblast-to-myofibroblast transition (FMT) leads to excessive extracellular matrix (ECM) deposition—a well-known hallmark of fibrotic disease. Transforming growth factor-β (TGF-β) is the primary cytokine driving FMT, and this phenotypic conversion is associated with mitochondrial dysfunction, notably a metabolic reprogramming towards enhanced glycolysis. The objective of this study was to examine whether the establishment of favorable metabolic phenotypes in TGF-β-stimulated fibroblasts could attenuate FMT. The hypothesis was that mitochondrial replenishment of TGF-β-stimulated fibroblasts would counteract a shift towards glycolytic metabolism, consequently offsetting pro-fibrotic processes. Isolated mitochondria, functionalized with a dextran and triphenylphosphonium (TPP) (Dex-TPP) polymer conjugate, were administered to fibroblasts (MRC-5 cells) stimulated with TGF-β, and effects on bioenergetics and fibrotic programming were subsequently examined. Results demonstrate that TGF-β stimulation of fibroblasts led to FMT, which was associated with enhanced glycolysis. Dex-TPP-coated mitochondria (Dex-TPP/Mt) delivery to TGF-β-stimulated fibroblasts abrogated a metabolic shift towards glycolysis and led to a reduction in reactive oxygen species (ROS) generation. Importantly, TGF-β-stimulated fibroblasts treated with Dex-TPP/Mt had lessened expression of FMT markers and ECM proteins, as well as reduced migration and proliferation. Findings highlight the potential of mitochondrial transfer, as well as other strategies involving functional reinforcement of mitochondria, as viable therapeutic modalities in fibrosis.
AB - Fibroblast-to-myofibroblast transition (FMT) leads to excessive extracellular matrix (ECM) deposition—a well-known hallmark of fibrotic disease. Transforming growth factor-β (TGF-β) is the primary cytokine driving FMT, and this phenotypic conversion is associated with mitochondrial dysfunction, notably a metabolic reprogramming towards enhanced glycolysis. The objective of this study was to examine whether the establishment of favorable metabolic phenotypes in TGF-β-stimulated fibroblasts could attenuate FMT. The hypothesis was that mitochondrial replenishment of TGF-β-stimulated fibroblasts would counteract a shift towards glycolytic metabolism, consequently offsetting pro-fibrotic processes. Isolated mitochondria, functionalized with a dextran and triphenylphosphonium (TPP) (Dex-TPP) polymer conjugate, were administered to fibroblasts (MRC-5 cells) stimulated with TGF-β, and effects on bioenergetics and fibrotic programming were subsequently examined. Results demonstrate that TGF-β stimulation of fibroblasts led to FMT, which was associated with enhanced glycolysis. Dex-TPP-coated mitochondria (Dex-TPP/Mt) delivery to TGF-β-stimulated fibroblasts abrogated a metabolic shift towards glycolysis and led to a reduction in reactive oxygen species (ROS) generation. Importantly, TGF-β-stimulated fibroblasts treated with Dex-TPP/Mt had lessened expression of FMT markers and ECM proteins, as well as reduced migration and proliferation. Findings highlight the potential of mitochondrial transfer, as well as other strategies involving functional reinforcement of mitochondria, as viable therapeutic modalities in fibrosis.
KW - Humans
KW - Signal Transduction
KW - Fibroblasts/metabolism
KW - Fibrosis
KW - Myofibroblasts/metabolism
KW - Transforming Growth Factor beta/metabolism
KW - Phenotype
KW - Mitochondria/metabolism
KW - Transforming Growth Factor beta1/metabolism
KW - Cells, Cultured
KW - glycolysis
KW - fibroblast-to-myofibroblast transition
KW - fibroblasts
KW - transforming growth factor-β
KW - mitochondrial transplantation
UR - http://www.scopus.com/inward/record.url?scp=85164963937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164963937&partnerID=8YFLogxK
U2 - 10.3390/ijms241310913
DO - 10.3390/ijms241310913
M3 - Article
C2 - 37446100
SN - 1422-0067
VL - 24
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 13
M1 - 10913
ER -